The Effectiveness of Adjuvant PD-1 Inhibitors in Patients with Surgically Resected Stage III/IV Acral Melanoma

Simple item page
dc.contributor.authorArak H.
dc.contributor.authorErkiliç S.
dc.contributor.authorYaslikaya Ş.
dc.contributor.authorEylemer Mocan E.
dc.contributor.authorAktaş G.
dc.contributor.authorÖzdemir M.
dc.contributor.authorSemiz H.S.
dc.contributor.authorKiliçkap S.
dc.contributor.authorÖzalp F.R.
dc.contributor.authorSever Ö.N.
dc.contributor.authorAkdaǧ G.
dc.contributor.authorAǧaoǧlu A.B.
dc.contributor.authorÖzçelik M.
dc.contributor.authorSari M.
dc.contributor.authorArcagök M.
dc.contributor.authorAnik H.
dc.contributor.authorYayla Ş.B.
dc.contributor.authorSever N.
dc.contributor.authorAçar F.P.
dc.contributor.authorBayrakçi İ.
dc.contributor.authorTurhal S.
dc.contributor.authorAyhan M.
dc.contributor.authorKuş T.
dc.date.accessioned2024-07-22T08:01:05Z
dc.date.available2024-07-22T08:01:05Z
dc.date.issued2024
dc.description.abstractOur aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters (P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents (P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies. © 2024 Lippincott Williams and Wilkins. All rights reserved.
dc.identifier.DOI-ID10.1097/CJI.0000000000000508
dc.identifier.issn15249557
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11318
dc.language.isoEnglish
dc.publisherLippincott Williams and Wilkins
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectChemotherapy, Adjuvant
dc.subjectFemale
dc.subjectHumans
dc.subjectImmune Checkpoint Inhibitors
dc.subjectMale
dc.subjectMelanoma
dc.subjectMiddle Aged
dc.subjectNeoplasm Staging
dc.subjectProgrammed Cell Death 1 Receptor
dc.subjectProto-Oncogene Mas
dc.subjectRetrospective Studies
dc.subjectSkin Neoplasms
dc.subjectTreatment Outcome
dc.subjectB Raf kinase
dc.subjectcarboplatin
dc.subjectdabrafenib
dc.subjectinterferon
dc.subjectipilimumab
dc.subjectlactate dehydrogenase
dc.subjectmitogen activated protein kinase
dc.subjectnivolumab
dc.subjectpaclitaxel
dc.subjectpembrolizumab
dc.subjectprogrammed death 1 receptor
dc.subjecttemozolomide
dc.subjecttrametinib
dc.subjectimmune checkpoint inhibitor
dc.subjectMAS receptor
dc.subjectMAS1 protein, human
dc.subjectPDCD1 protein, human
dc.subjectprogrammed death 1 receptor
dc.subjectacral melanoma
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectcancer adjuvant therapy
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectclinical assessment
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectdisease free survival
dc.subjectdistant metastasis
dc.subjectdrug efficacy
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectlymph node metastasis
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmelanoma
dc.subjectmiddle aged
dc.subjectmulticenter study (topic)
dc.subjectmultiple cycle treatment
dc.subjectmultivariate analysis
dc.subjectobservational study
dc.subjectoverall survival
dc.subjectpersonal experience
dc.subjectretrospective study
dc.subjectstatistically significant result
dc.subjecttreatment duration
dc.subjecttreatment indication
dc.subjecttumor localization
dc.subjectvery elderly
dc.subjectadjuvant chemotherapy
dc.subjectclinical trial
dc.subjectmelanoma
dc.subjectmortality
dc.subjectmulticenter study
dc.subjectpathology
dc.subjectprocedures
dc.subjectskin tumor
dc.subjecttreatment outcome
dc.titleThe Effectiveness of Adjuvant PD-1 Inhibitors in Patients with Surgically Resected Stage III/IV Acral Melanoma
dc.typeArticle

Files

Collections

Scopus Koleksiyonu